Advancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivation - 17/06/23

Doi : 10.1016/j.biopha.2023.114916

Haiqi Tan ^a,^b,^{^{1
These authors contributed equally to this work.}}, Yibing Gong ^a,^b,^{^{1
These authors contributed equally to this work.}}, Yi Liu ^a,^b, Jingyi Long ^a,^b, Qingshuang Luo ^a,^b, Oluwasijibomi Damola Faleti ^a,^b,^c, Xiaoming Lyu ^a,^b,^⁎
^a Department of Laboratory Medicine, The Third Affiliated Hospital, Southern Medical University, Guangzhou 510630, China
^b The Third School of Clinical Medicine, Southern Medical University, Guangzhou 510630, China
^c Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, 999000, Hong Kong Special Administrative Region of China

^⁎Correspondence to: Department of Laboratory Medicine, The Third School of Clinical Medicine and The Third Affiliated Hospital, Southern Medical University, Guangzhou 510630, China.Department of Laboratory Medicine, The Third School of Clinical Medicine and The Third Affiliated Hospital, Southern Medical UniversityGuangzhou510630China

Abstract

Epstein-Barr virus (EBV) is a widespread human herpes virus associated with lymphomas and epithelial cell cancers. It establishes two separate infection phases, latent and lytic, in the host. Upon infection of a new host cell, the virus activates several pathways, to induce the expression of lytic EBV antigens and the production of infectious virus particles. Although the carcinogenic role of latent EBV infection has been established, recent research suggests that lytic reactivation also plays a significant role in carcinogenesis. In this review, we summarize the mechanism of EBV reactivation and recent findings about the role of viral lytic antigens in tumor formation. In addition, we discuss the treatment of EBV-associated tumors with lytic activators and the targets that may be therapeutically effective in the future.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract

Targeting lytic activators and other targets of Epstein-Barr Virus (EBV)-associated tumors may provide promising therapeutic options.

Targeting lytic activators and other targets of Epstein-Barr Virus (EBV)-associated tumors may provide promising therapeutic options.ga1

Le texte complet de cet article est disponible en PDF.

Highlights

•	EBV lytic activation play a significant role in carcinogenesis.
•	Mechanisms of EBV reactivation in relation to tumors are being investigated to understand its role in carcinogenesis.
•	Treatment of EBV-associated tumors with lytic activators and other targets is being explored for possible therapeutic use.
•	Oncogenic mechanisms of EBV lytic reactivation could contribute to the development of innovative therapeutics for EBV-associated malignancies.

Le texte complet de cet article est disponible en PDF.

Keywords : EBV, Lytic reactivation, Carcinogenesis, Therapies